2 juin 2023 - Pharma FDF

ONConcept® successfully completes Pivotal BE Study

We are excited to share that ONConcept® has successfully completed the pivotal BE study for Pomalidomide against the EU reference product 4 mg (Imnovid).
This is a great achievement and yet another milestone in our journey. The ONConcept team is now focused on preparing the dossier for EU submission this August.

ONConcept® is the result of a powerful strategic collaboration in the field of oncology. This partnership brings together three independent, certified European pharmaceutical companies - Bluepharma, HELM AG, and WELDING GmbH & Co. KG.

The goal of this union is to create a leading partnership for complex, differentiated, and high potency products. The combined expertise and experience of these companies will enable them to deliver innovative treatments and technologies made in the EU to patients in need.

If you have any further questions or require additional information, please do not hesitate to reach out to us.